📉 In a randomized trial with 48 patients diagnosed with #AlcoholUseDisorder, semaglutide significantly lowered alcohol intake in a controlled lab setting.
🚬 Interestingly, nicotine consumption also decreased.
💉 Low doses (0.25-1 mg/week) were used over 9 weeks—much lower than standard obesity or diabetes dosing.
🔬 More research is needed, but this adds to growing evidence that GLP-1 agonists may impact addictive behaviors.
Link to article: https://pubmed.ncbi.nlm.nih.gov/39937469/